Two GHRH-analog cousins
CJC-1295 and sermorelin are both discussed as GHRH analogs—synthetic peptides modeled on growth-hormone-releasing hormone that speak to the GHRH receptor. Unlike a GHRH-versus-ghrelin comparison, these two share the same receptor language and differ mainly in engineering and half-life. This page describes research-compound mechanism for educational purposes only and is not medical advice or a usage recommendation.
Sermorelin: GHRH (1-29)
Sermorelin corresponds essentially to the first 29 amino acids of GHRH—GHRH (1-29)—the shortest fragment that retains the relevant receptor activity in discussion. As a close mimic of the natural sequence, it is associated with a short half-life, because it is subject to the same rapid enzymatic breakdown that limits native GHRH. It is the baseline against which the CJC-1295 modifications are usually described.
CJC-1295 and the DAC question
CJC-1295 builds on the modified GRF (1-29) idea with substitutions that resist degradation. The pivotal distinction in the marketplace is “with DAC” versus “without DAC.” DAC stands for Drug Affinity Complex, a modification intended to bind albumin and substantially extend half-life. “CJC-1295 without DAC” is often used interchangeably with “modified GRF 1-29,” which is why naming confusion is rampant and analytical identity matters.
Half-life: the core contrast
The practical axis of comparison is duration of exposure. Sermorelin and no-DAC modified GRF variants are discussed as short-acting. The DAC version of CJC-1295 is the design intended for a much longer half-life via albumin binding. Because vendor labels are inconsistent, the only reliable way to know what a research vial actually contains is mass and sequence confirmation, not the name on the label.
Why ipamorelin often enters the discussion
GHRH analogs like these are frequently discussed alongside ipamorelin, which acts on a different receptor—the ghrelin receptor GHS-R1a—rather than the GHRH receptor. Online communities pair a GHRH analog with a ghrelin-pathway peptide as a “complementary” narrative. That pairing is a forum convention, not a validated protocol, and is noted here only to explain the common cross-references.
Regulatory framing
Both CJC-1295 and sermorelin are commonly sold as research materials rather than authorized medicines in this context. In Canada, peptides marketed for human use without authorization are treated as unapproved drugs, and “research use only” labeling does not change that classification. All such compounds carry unestablished safety; this section is descriptive, not a suggestion to use them.
Sources and what they cover
These primary studies, official records and standards cover the topics linked below. The scope notes distinguish laboratory findings, human trials and regulatory records. This is a selected bibliography, not a systematic review or verification of every sentence; absence of a study here does not prove that no study exists.
- Thorner et al. (1996) — GHRH treatment in children with GH deficiency
Specific pediatric GH-deficiency study; not a head-to-head trial against CJC-1295 or a healthy-adult longevity study.
Relevant sections: Sermorelin: GHRH (1-29)
- Teichman et al. (2006) — CJC-1295 in healthy adults
Human pharmacokinetic and GH/IGF-1 study of CJC-1295 with DAC; not evidence for every product sold as CJC-1295.
Relevant sections: CJC-1295 and the DAC question · Half-life: the core contrast
- Raun et al. (1998) — Ipamorelin, a selective growth hormone secretagogue
Original preclinical receptor and hormone-release work; does not validate consumer stacks or human recovery claims.
Relevant sections: Why ipamorelin often enters the discussion
- Health Canada (2026) — unauthorized injectable peptides bought online
Canadian safety and authorization notice for the products described. It does not establish approval status in every country.
Relevant sections: Regulatory framing
FAQ
What is the main difference between CJC-1295 and sermorelin?+
Both are GHRH analogs acting on the GHRH receptor, but they differ in engineering and half-life. Sermorelin closely mimics GHRH (1-29) and is short-acting, while CJC-1295—especially with DAC—is designed for a longer half-life. This is educational information, not medical advice.
What does DAC mean?+
DAC stands for Drug Affinity Complex, a modification intended to bind albumin and extend half-life. “CJC-1295 with DAC” is the long-acting design, while “without DAC” is often used interchangeably with modified GRF 1-29. Marketplace naming is inconsistent, so analytical identity matters.
Are these approved for human use?+
They are generally sold as research materials, not authorized medicines. In Canada, peptides marketed for human use without authorization are treated as unapproved drugs, and RUO labeling does not create a legal exemption. Their safety is unestablished.